Targeting CD99 in association with doxorubicin: An effective combined treatment for Ewing’s sarcoma
- 31 January 2006
- journal article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 42 (1), 91-96
- https://doi.org/10.1016/j.ejca.2005.09.015
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Molecular mechanisms of CD99-induced caspase-independent cell death and cell–cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediatorsOncogene, 2004
- Long-Term Event-Free Survival After Intensive Chemotherapy for Ewing’s Family of Tumors in Children and Young AdultsJournal of Clinical Oncology, 2003
- Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of BoneThe New England Journal of Medicine, 2003
- Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic InstituteEuropean Journal of Cancer, 2002
- CD99 isoform expression dictates T‐cell functional outcomesThe FASEB Journal, 2002
- CD99 plays a major role in the migration of monocytes through endothelial junctionsNature Immunology, 2002
- Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch studyAnnals of Oncology, 2001
- CD99 (E2) up-regulates α 4β 1-dependent T cell adhesion to inflamed vascular endothelium under flow conditionsEuropean Journal of Immunology, 2000
- Engagement of CD99 Induces Apoptosis Through a Calcineurin-Independent Pathway in Ewing's Sarcoma CellsThe American Journal of Pathology, 1998
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984